RCM
CRSP icon

Ravenstone Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Ravenstone Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-800
Closed -$32.5K – 36
2022
Q4 		$32.5K Hold
800
– – 0.03% 27
2022
Q3 		$52.3K Hold
800
– – 0.05% 25
2022
Q2 		$48.6K Hold
800
– – 0.04% 26
2022
Q1 		$50.2K Hold
800
– – 0.03% 27
2021
Q4 		$60.6K Hold
800
– – 0.04% 28
2021
Q3 		$89.5K Buy
+800
New +$100K 0.07% 29

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ravenstone Capital Management's CRSP Position: Q1 2023 in Review

Ravenstone Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 800 shares — an estimated $32.5K sold.

Ravenstone Capital Management first reported a position in CRSP in Q3 2021 and held it in 6 quarters. The position peaked at $89.5K in Q3 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

  • Ravenstone Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ravenstone Capital Management sold 800 CRISPR Therapeutics shares in Q1 2023, an estimated $32.5K.
  • Ravenstone Capital Management first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 6 quarters.
  • Ravenstone Capital Management's CRISPR Therapeutics position peaked at $89.5K in Q3 2021.
  • 381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Ravenstone Capital Management's 13F filing for Q1 2023, filed 26 Jun 2026.